Peter Mac’s Professor John Seymour AM has been ranked in the top 0.1% of scholars writing about Lymphoid Leukemia globally over the past decade, Expertscape has announced this week. 

This achievement recognises Professor Seymour’s game-changing work that’s helping blood cancer patients across the world. 

He is part of the team that developed the drug Venetoclax from basic research, through clinical trials, to its position today - a blood cancer drug used around the world.

A clinical haematologist and Associate Director of Clinical Research at the Peter Mac and the Director of the integrated Haematology Department at Peter Mac & the Royal Melbourne Hospital, he has authored 18 book chapters, more than 500 peer reviewed publications (with more than 25,000 literature citations), and more than 700 conference abstracts. 

Actively involved in a broad range of collaborative research, Professor Seymour has been been the principal investigator on more than 85 clinical trials and chief investigator on competitive grants awarded more than AUD$18 million funding in the last 10 years. 

In 2015 he was awarded Membership of the Order of Australia, and elected to the Australian Academy of Health and Medical Sciences for his contributions to the field.